stockrow
Sunday 8 November 2026
Export GRFS’s income statement to Excel — free account
Grifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
8.43
0.03
−0.35%
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Shares outstanding
Grifols, S.A.'s shares outstanding at the end of fiscal 2025 was $681.6M, unchanged from fiscal 2024. Over the past ten years it has ranged from $677.1M (fiscal 2023) to $685.7M (fiscal 2015); the current reading is higher than 45% of that period. Grifols, S.A. ranks 13th of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $681.6M | 0.28% |
| FY2024 | $679.7M | 0.38% |
| FY2023 | $677.1M | (0.32%) |
| FY2022 | $679.3M | (0.31%) |
| FY2021 | $681.4M | (0.55%) |
| FY2020 | $685.1M | 0.06% |
| FY2019 | $684.7M | 0.00% |
| FY2018 | $684.7M | 0.06% |
| FY2017 | $684.2M | 0.15% |
| FY2016 | $683.2M | (0.35%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Dec 2025 | $681.6M | (1.02%) |
| Jun 2025 | $688.6M | (7.20%) |
| Jun 2024 | $742.1M | — |
| Sep 2023 | $0.00 | — |
| 22 more quarters | Free account |
Against its own ten years
Low $677.1M
High $685.7M
Ten-year median
$683.2M
Current reading's percentile
45
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| NVO Novo Nordisk A/S compare | $4.4B |
| SNY Sanofi compare | $2.4B |
| BMY Bristol Myers Squibb Company compare | $2.1B |
| GSK GSK PLC Sponsored ADR compare | $2.0B |
| GRFS Grifols, S.A. | $681.6M |
| OGN Organon & Co. compare | $272.4M |
| BIIB Biogen Inc. compare | $147.8M |
| AMRN Amarin Corporation PLC compare | $21.4M |
| NSRX Nasus Pharma Ltd. compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement